Novavax, Inc. (NVAX) Stock Forecast
NVAX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.67 / 5 from 9 analysts
- Price target
- $14.22 average of analyst targets
- Upside to target
- +26.3% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.33
- 52-week range
- $6.22 – $12.82
NVAX analyst ratings
9 analystsNumber of analysts at each rating.
NVAX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NVAX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.22 | −$0.47 | $0.50 | −$1.25 | +82.4% | 7 |
| Current fiscal year (2026) | −$0.52 | −$1.32 | $0.48 | $2.58 | −120.1% | 8 |
| Next fiscal year (2027) | −$0.08 | −$0.85 | $0.67 | −$0.52 | +84.0% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NVAX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $74.6M | $33.1M | $178.6M | +5.9% | 7 |
| Current fiscal year (2026) | $389.3M | $262.4M | $508.1M | −65.3% | 8 |
| Next fiscal year (2027) | $290.3M | $140.6M | $451.8M | −25.4% | 8 |
NVAX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NVAX revenue: reported and forecast
NVAX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.02 | −$0.18 | −$0.18 | −$0.18 | −$0.22 | +905.5% | 1 up · 1 down |
| Current fiscal year (2026) | −$0.47 | −$0.63 | −$0.63 | −$0.64 | −$0.52 | +9.9% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.25 | −$0.22 | −$0.22 | −$0.12 | −$0.08 | −67.4% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NVAX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NVAX beat in 8 of 12.
What analysts expect from NVAX
9 analysts cover Novavax; their consensus rating is buy (3.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $14.22, 26.3% above the latest close of $11.26. Analysts expect earnings of −$0.52 per share for 2026, −120.1% from a year earlier. For 2027 the average estimate is −$0.08 per share on revenue of $290.3 million. Novavax beat the EPS estimate in 8 of the last 12 quarters.
Related: NVAX income statement, NVAX key metrics, NVAX chart. See the NVAX stock overview for the latest quote and news.
NVAX forecast FAQ
What is Novavax's price target?
The average analyst price target for Novavax is $14.22, 26.3% above the latest close of $11.26.
Is Novavax a buy, hold or sell?
Of 9 analysts covering Novavax, 5 rate it a strong buy, 0 a buy, 1 a hold, 2 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Novavax's EPS forecast?
Analysts forecast −$0.52 per share for 2026 (range −$1.32 to $0.48); for 2027 the estimate is −$0.08.
What is Novavax's revenue forecast?
The average revenue estimate for 2026 is $389.3 million, growth of −65.3%; for 2027 it is $290.3 million.
When does Novavax report earnings?
Novavax is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.33.
Does Novavax usually beat earnings estimates?
Novavax reported EPS at or above the analyst estimate in 8 of the last 12 quarters.